31/10/2022 (Agence Europe) – The European Medicines Agency (EMA) announced on 28 October the publication of clinical data supporting the authorisation of Comirnaty, the bivalent messenger RNA vaccine developed by Pfizer and BioNTech and suitable for use against the original SARS-CoV-2 strain and its sub-variant of concern BA.1. This publication is made under exceptional measures related to the Covid-19 pandemic. The vaccine was authorised by the European Commission on 1 September (see...